Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3609-3613

  Conte Jr , John E ^a,b   DeVoe, Catherine ^a   Little, Emily ^a,b   Golden, Jeffrey A ^b  

^a American Health Sciences   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE;

ADULT; APPETITE; ARTHRALGIA; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BLOATING; BLOOD SAMPLING; BRONCHOSCOPY; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; EPISTAXIS; FATIGUE; FEMALE; GRAFT RECIPIENT; HUMAN; LIPID DIET; LIQUID CHROMATOGRAPHY; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; LUNG FLUID; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SIDE EFFECT; STEADY STATE; TANDEM MASS SPECTROMETRY;

ADULT; AGED; CHROMATOGRAPHY, LIQUID; EPITHELIUM; FEMALE; HUMANS; LUNG; LUNG TRANSPLANTATION; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ALVEOLI; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 77956104053     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01396-09     Document Type: Article

References (27)

1. Andes, D., K. Marchillo, R. Conklin, G. Krishna, F. Ezzet, A. Cacciapuoti, and D. Loebenberg. 2004. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48:137-142.
2. Capitano, B., B. A. Potoski, S. Husain, S. Zhang, D. L. Paterson, S. M. Studer, K. R. McCurry, and R. Venkataramanan. 2006. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob. Agents Chemother. 50:1878-1880.
3. Catanzaro, A., G. A. Cloud, D. A. Stevens, B. E. Levine, P. L. Williams, R. H. Johnson, A. Rendon, L. F. Mirels, J. E. Lutz, M. Holloway, and J. N. Galgiani. 2007. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin. Infect. Dis. 45:562-568.
4. Conte, J. E., Jr., J. A. Golden, J. Kipps, M. McIver, and E. Zurlinden. 2004. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob. Agents Chemother. 48:3823-3827.
5. Conte, J. E., Jr., J. A. Golden, G. Krishna, M. McIver, E. Little, and E. Zurlinden. 2009. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother. 53:703-707.
6. Conte, J. E., Jr., J. A. Golden, M. McIver, E. Little, and E. Zurlinden. 2007. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int. J. Antimicrob. Agents 30:422-427.
7. Courtney, R., A. Sansone, W. Smith, T. Marbury, P. Statkevich, M. Martinho, M. Laughlin, and S. Swan. 2005. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. 45:185-192.
8. Courtney, R., D. Wexler, E. Radwanski, J. Lim, and M. Laughlin. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222.
9. Diekema, D. J., S. A. Messer, R. J. Hollis, R. N. Jones, and M. A. Pfaller. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41:3623-3626.
10. Ezzet, F., D. Wexler, R. Courtney, G. Krishna, J. Lim, and M. Laughlin. 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44:211-220.
11. Groll, A. H., and T. J. Walsh. 2006. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 49(Suppl. 1):7-16.
12. Krieter, P., B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. Courtney. 2004. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother. 48:3543-3551.
13. Krishna, G., M. AbuTarif, F. Xuan, M. Martinho, D. Angulo, and O. A. Cornely. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232.
14. Krishna, G., A. Moton, L. Ma, M. M. Medlock, and J. McLeod. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966.
15. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48:201-205.
16. Raad, I. I., H. A. Hanna, M. Boktour, Y. Jiang, H. A. Torres, C. Afif, D. P. Kontoyiannis, and R. Y. Hachem. 2008. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22:496-503.
17. Ramani, R., and V. Chaturvedi. 2007. Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and nonendemic areas. Mycopathologia 163:315-319. (Pubitemid 46919105)
18. Saag, M. S., R. J. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, W. G. Powderly, J. D. Sobel, and W. E. Dismukes. 2000. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30:710-718.
19. Sabatelli, F., R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
20. Sansone-Parsons, A., G. Krishna, M. Martinho, B. Kantesaria, S. Gelone, and T. G. Mant. 2007. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 27:825-834.
21. Sansone-Parsons, A., G. Krishna, J. Simon, P. Soni, B. Kantesaria, J. Herron, and R. Stoltz. 2007. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 51:495-502.
22. Segal, B. H. 2007. Role of macrophages in host defense against aspergillosis and strategies for immune augmentation. Oncologist 12(Suppl. 2):7-13.
23. van Burik, J. A., R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:e61-e65.
24. Waldorf, A. R. 1989. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol. Ser. 47:243-271.
25. Waldorf, A. R., S. M. Levitz, and R. D. Diamond. 1984. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J. Infect. Dis. 150:752-760.
26. Walsh, T. J., I. Raad, T. F. Patterson, P. Chandrasekar, G. R. Donowitz, R. Graybill, R. E. Greene, R. Hachem, S. Hadley, R. Herbrecht, A. Langston, A. Louie, P. Ribaud, B. H. Segal, D. A. Stevens, J. A. van Burik, C. S. White, G. Corcoran, J. Gogate, G. Krishna, L. Pedicone, C. Hardalo, and J. R. Perfect. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12.
27. Wheat, L. J., P. Connolly, M. Smedema, M. Durkin, E. Brizendine, P. Mann, R. Patel, P. M. McNicholas, and M. Goldman. 2006. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J. Antimicrob. Chemother. 57:1235-1239.